Brinza Crischentian, Floria Mariana, Popa Iolanda Valentina, Burlacu Alexandru
Faculty of Medicine, University of Medicine and Pharmacy, 700115 Iasi, Romania.
Institute of Cardiovascular Diseases, 700503 Iasi, Romania.
Diagnostics (Basel). 2022 Feb 13;12(2):476. doi: 10.3390/diagnostics12020476.
The potential benefit of ferritin evaluation resides in its association with adverse outcomes in patients with various pathological conditions. We aimed to conduct the first systematic review evaluating the association between ferritin levels and adverse cardiovascular outcomes in patients with acute myocardial infarction (AMI) during short- or long-term follow-up. Seven studies investigating various endpoints (mortality, major adverse cardiovascular events-MACE, the decline of the left ventricular ejection fraction-LVEF, left ventricular aneurysm development-LVA) were included. AMI patients with low or increased ferritin values tended to have higher in-hospital and 30-day mortality rates. Low and high ferritin levels and chronic kidney disease were independently associated with increased risk of LVA formation. High ferritin concentrations were linked to an accentuated LVEF decline in ST-elevation myocardial infarction patients treated by percutaneous coronary intervention. Both low and high ferritin values were also associated with the duration of hospitalization in patients with AMI during hospital stay and at more extended follow-up. Ferritin evaluation represents a simple investigation that could identify high-risk patients with AMI who might benefit from closer monitoring and specific therapeutic interventions. These data should be confirmed in large trials in the context of currently available therapies for heart failure and AMI.
铁蛋白评估的潜在益处在于其与各种病理状况患者的不良结局相关。我们旨在进行首次系统评价，评估急性心肌梗死（AMI）患者在短期或长期随访中铁蛋白水平与不良心血管结局之间的关联。纳入了七项研究，这些研究调查了各种终点（死亡率、主要不良心血管事件-MACE、左心室射血分数-LVEF下降、左心室动脉瘤形成-LVA）。铁蛋白值低或升高的AMI患者往往有更高的住院死亡率和30天死亡率。低铁蛋白水平、高铁蛋白水平和慢性肾脏病与LVA形成风险增加独立相关。高铁蛋白浓度与接受经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者的LVEF加速下降有关。低铁蛋白值和高铁蛋白值也与AMI患者住院期间及更长时间随访的住院时间有关。铁蛋白评估是一项简单的检查，可识别可能从密切监测和特定治疗干预中获益的高危AMI患者。这些数据应在针对心力衰竭和AMI的现有治疗背景下的大型试验中得到证实。
